TY - JOUR T1 - Alternative Translation Initiation of Human Regulators of G-Protein Signaling-2 Yields a Set of Functionally Distinct Proteins JF - Molecular Pharmacology JO - Mol Pharmacol SP - 1 LP - 11 DO - 10.1124/mol.107.036285 VL - 73 IS - 1 AU - Steven Gu AU - Annepa Anton AU - Samina Salim AU - Kendall J. Blumer AU - Carmen W. Dessauer AU - Scott P. Heximer Y1 - 2008/01/01 UR - http://molpharm.aspetjournals.org/content/73/1/1.abstract N2 - The regulator of G-protein signaling (RGS2) contains a characteristic RGS domain flanked by short amino and carboxyl terminal sequences. The RGS domain mediates inhibition of Gαq and Gαi signaling, whereas the amino terminal domain (NTD) directs interaction with adenylyl cyclases, G-protein-coupled receptors, and other signaling partners. Here, we identify a set of novel RGS2 protein products that differ with respect to their amino terminal architecture and functional characteristics. An RGS2 expression reporter cassette revealed four distinct open reading frames (ORFs) that can be expressed from the RGS2 NTD. We hypothesized that alternative translation initiation from four AUG codons corresponding to amino acid positions 1, 5, 16, and 33 could produce the observed RGS2 expression profile. Selective disruption of each AUG confirmed that alternate sites of translation initiation accounted for each of the observed products. Proteins derived from ORFs 1 to 4 showed no difference in Gαq inhibitory potential or recruitment from the nucleus in response to Gαq signaling. By contrast, RGS2 products initiating from methionines at positions 16 (ORF3) and 33 (ORF4) were impaired as inhibitors of type V adenylyl cyclase (ACV) compared with full-length RGS2. We predicted that regulation of the RGS2 expression profile would allow cells to adapt to changing signaling conditions. Consistent with this model, activation of Gαs/ACV but not Gαq signaling increased the relative abundance of the full-length RGS2 protein, suggesting that alternative translation initiation of RGS2 is part of a novel negative feedback control pathway for adenylyl cyclase signaling. The American Society for Pharmacology and Experimental Therapeutics ER -